NYSDA Publications

FDA Authorizes Use of Bivalent Moderna and Pfizer COVID-19 Vaccines in Younger Age Groups

The United States Food and Drug Administration (FDA) has authorized use of the Moderna COVID-19 Vaccine, Bivalent, and the Pfizer COVID-19 Vaccine, Bivalent, as a single booster dose in younger age groups.  FDA notes that the Moderna COVID-19 Vaccine, Bivalent, is authorized for administration at least two months following completion of primary or booster vaccination in children down to six years of age and that the Pfizer COVID-19 Vaccine, Bivalent, is authorized for administration at least two months following completion of primary or booster vaccination in children down to five years of age.  To read the FDA announcement and summary of the authorization of the use of the bivalent Moderna and Pfizer COVID-19 vaccines in younger age groups, use the link below.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-bivalent-covid-19-vaccines?utm_medium=email&utm_source=govdelivery
22380292641